PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I-IIIA opera...
J. Pérez-García, J. Cortés, M. Ruíz-Borrego et al.· Nature Medicine· 0 citations
An artificial intelligence (AI)-based deep-learning model enables accurate inference of a clinically validated immune gene-expression program directly from routine H&E slides and is independently associated with survival and pCR to NACT/NACTIT in eBC.
F. Bertucci, Gwenael Lumet, Mathieu Delattre et al.· Journal of Translational Med...· 0 citations
BACKGROUND
We evaluated pembrolizumab plus chemotherapy versus chemotherapy alone in participants with PD-L1‒positive, hormone receptor-positive (HR+)/HER2- advanced breast cancer after progression on prior endocrine-based therapy (ET).
PATIENTS AND METHODS
Participants with locally recurrent inoperable or metastatic...
H. Rugo, M. Kok, A. Gonçalves et al.· Annals of Oncology· 0 citations
PURPOSE Prognostic biomarkers that estimate residual recurrence risk after standard adjuvant therapy to guide further treatment escalation are an unmet clinical need. This study used Ataraxis Breast CTX, a causal multi-modal AI model integrating clinical variables and histopathology, to stratify residual risk in clinic...
T. Bachelot, S. Chabaud, J. Lemonnier et al.· medRxiv· 1 citation
Clinical variables alone had limited predictive value, supporting the need for molecular and immune biomarkers to better identify this subgroup of patients with HER2-positive metastatic breast cancer.
T. Grinda, M. Carton, S. Morganti et al.· Breast· 0 citations
Trastuzumab deruxtecan (T-DXd) is the current standard second-line therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and it has been recently approved by FDA as first line therapy in combination with pertuzumab, following the results of the DESTINY-Breast09 trial. Howe...
J. Frenel, A. de Nonnevile, C. Guérin-Charbonnel et al.· Breast· 0 citations
The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons, and out-performed existing recurrence-score-based tests.
D. Biswas, Jeroen Berrevoets, A. McClean et al.· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.